This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medical Product Stock Earnings on May 2: CERN, ABC & More
by Zacks Equity Research
Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.
Masimo Gets CE Mark for NomoLine, Expands in Capnography
by Zacks Equity Research
Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.
Why Masimo (MASI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) can be a harbinger of outperformance and a signal for a strong earnings profile on the back of solid Zacks rank and positive earnings ESP.
Masimo (MASI) Launches UniView, Improves Patient Safety
by Zacks Equity Research
Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides on solid earnings results and a wide array of products.
Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive
by Zacks Equity Research
Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.
Masimo Products to Boost India-Based NU Hospitals' Systems
by Zacks Equity Research
Masimo's (MASI) flagship technologies to be incorporated in India-based NU Hospitals' continuum of care.
Masimo's SpHb Hemoglobin Monitoring Study Results Positive
by Zacks Equity Research
New study proves that Masimo's (MASI) noninvasive SpHb is more efficient in hemoglobin monitoring when compared to invasive LabHb.
Masimo's (MASI) Eve Gets CE Mark, Bolsters CCHD Diagnosis
by Zacks Equity Research
Masimo's (MASI) newborn screening application, Eve, will make CCHD diagnosis simple and cost effective.
Masimo (MASI) Receives FDA Approval for SedLine, Shares Up
by Zacks Equity Research
Masimo (MASI) to overhaul neurological diagnoses with its next generation SedLine brain function monitoring.
Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home
by Zacks Equity Research
Masimo (MASI) states that with its inherent touchscreen interface, Rad-97 is user-friendly for clinicians and non-clinicians and can be easily tailored to cater to the needs of home users.
Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
by Zacks Equity Research
Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.
Robust Pipeline Aids Edwards Lifesciences, Rising Costs Ail
by Zacks Equity Research
Edwards Lifesciences' (EW) pipeline building to fortify foothold across all operating businesses bodes well. Also, the TAVR adoption rate across Japan and the European countries is impressive.
Align Rides on Balanced Segmental Growth Amid Stiff Contest
by Zacks Equity Research
Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
5 MedTech Stocks to Beat Tax Hazards With Positive Returns
by Zacks Equity Research
Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) continues to grow on innovation and product launches.
Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View
by Zacks Equity Research
Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.
Masimo (MASI) Launches Trace Data and Reporting Tool in US
by Zacks Equity Research
Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.
Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
by Zacks Equity Research
Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.
Abbott to Gain from Alere's Takeover Due for Oct 3 Closure
by Zacks Equity Research
Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.
Masimo RAS-45 Full-Market Release to Boost Respiratory Care
by Zacks Equity Research
Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.
Here's Why Investors Should Buy Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.